Bilibili Inc vs 10X Genomics Inc — how do they compare? Bilibili Inc trades at $17.44 (market cap $7.65B), while 10X Genomics Inc trades at $57.65 (market cap $7.61B). The key difference: Bilibili Inc and 10X Genomics Inc are close in size by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.
| BILI | TXG | |
|---|---|---|
Market Cap | $7.65B | $7.61B |
Sector | Media | Health |
52-Week High | $35.92 | $58.57 |
52-Week Low | $15.96 | $11.34 |
Enterprise Value | $5.49B | $7.14B |
Signals from Pluang's Aura AI — not financial advice
Bilibili (BILI) trades at $17.48, down 7.95% over 24 hours, reflecting bearish technical momentum. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.19 versus $0.17 expected, and revenue growth to $30.35 billion in 2025. Analyst sentiment remains overwhelmingly bullish with 20 buy ratings out of 24, supported by a $300 million share repurchase program announced June 24, 2026.
The outlook is positive given robust user engagement and advertising growth, but risks include competitive pressures and reliance on Chinese market dynamics. Valuation metrics like a P/E of 36.24 suggest premium pricing, requiring sustained execution to justify upside. Near-term focus is on Q2 2026 earnings due August 27, 2026, which could catalyze movement.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Trailing returns across standard periods
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →